Drug-Loaded Tumor-Derived Microparticles Elicit CD8+ T Cell-Mediated Anti-Tumor Response in Hepatocellular Carcinoma

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Intl J Cancer. 2021;149(4):778–789. doi:10.1002/ijc.33588
   Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA a Cancer J Clinicians. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Lan T, Li H, Zhang D, et al. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Mol Cancer. 2019;18(1):186. doi:10.1186/s12943-019-1106-z
   PubMed Web of Science ®Google Scholar
• Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta‐analysis. Hepatology. 2018;67(1):381–400. doi:10.1002/hep.29485
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a Phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344–1354. doi:10.1016/S1470-2045(15)00198-9
   PubMed Web of Science ®Google Scholar
• Lu LC, Cheng AL, Poon R. recent advances in the prevention of hepatocellular carcinoma recurrence. Semin Liver Dis. 2014;34(04):427–434. doi:10.1055/s-0034-1394141
   PubMedGoogle Scholar
• Kassel R, Cruise MW, Iezzoni JC, Taylor NA, Pruett TL, Hahn YS. Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology. 2009;50(5):1625–1637. doi:10.1002/hep.23173
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Zhang J, Dang F, Ren J, Wei W. Biochemical aspects of pd-l1 regulation in cancer immunotherapy. Trends Biochem Sci. 2018;43(12):1014–1032. doi:10.1016/j.tibs.2018.09.004
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550. doi:10.1038/s41591-018-0014-x
   PubMed Web of Science ®Google Scholar
• Tominaga N, Yoshioka Y, Ochiya T. A novel platform for cancer therapy using extracellular vesicles. Adv Drug Delivery Rev. 2015;95:50–55. doi:10.1016/j.addr.2015.10.002
   PubMed Web of Science ®Google Scholar
• Colombo M, Raposo G, Biogenesis TC. Secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30(1):255–289. doi:10.1146/annurev-cellbio-101512-122326
   PubMed Web of Science ®Google Scholar
• D’Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev. 2012;26(12):1287–1299. doi:10.1101/gad.192351.112
   PubMed Web of Science ®Google Scholar
• Lee TH, D’Asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J. Microvesicles as mediators of intercellular communication in cancer—the emerging science of cellular ‘debris. Semin Immunopathol. 2011;33(5):455–467. doi:10.1007/s00281-011-0250-3
   PubMed Web of Science ®Google Scholar
• Quesenberry PJ, Aliotta JM. Cellular phenotype switching and microvesicles. Adv Drug Delivery Rev. 2010;62(12):1141–1148. doi:10.1016/j.addr.2010.06.001
   PubMed Web of Science ®Google Scholar
• Tang K, Zhang Y, Zhang H, et al. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat Commun. 2012;3(1):1282. doi:10.1038/ncomms2282
   PubMedGoogle Scholar
• Zhang H, Tang K, Zhang Y, et al. Cell-free tumor microparticle vaccines stimulate dendritic cells via cgas/sting signaling. Cancer Immunol Res. 2015;3(2):196–205. doi:10.1158/2326-6066.CIR-14-0177
   PubMed Web of Science ®Google Scholar
• Ortiz-Bonilla CJ, Uccello TP, Gerber SA, Lord EM, Messing EM, Lee YF. Bladder cancer extracellular vesicles elicit a CD8 T cell-mediated antitumor immunity. IJMS. 2022;23(6):2904. doi:10.3390/ijms23062904
   Google Scholar
• Ma J, Zhang Y, Tang K, et al. Reversing drug resistance of soft tumor-repopulating cells by tumor cell-derived chemotherapeutic microparticles. Cell Res. 2016;26(6):713–727. doi:10.1038/cr.2016.53
   PubMed Web of Science ®Google Scholar
• Guo M, Wu F, Hu G, et al. Autologous tumor cell–derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion. Sci Transl Med. 2019;11(474):eaat5690. doi:10.1126/scitranslmed.aat5690
   PubMed Web of Science ®Google Scholar
• Wan C, Sun Y, Tian Y, et al. Irradiated tumor cell–derived microparticles mediate tumor eradication via cell killing and immune reprogramming. Sci Adv. 2020;6(13):eaay9789. doi:10.1126/sciadv.aay9789
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang H, Zhou N, et al. Methotrexate-loaded tumour-cell-derived microvesicles can relieve biliary obstruction in patients with extrahepatic cholangiocarcinoma. Nat Biomed Eng. 2020;4(7):743–753. doi:10.1038/s41551-020-0583-0
   PubMed Web of Science ®Google Scholar
• Wei K, Zhang H, Yang S, et al. Chemo-drugs in cell microparticles reset antitumor activity of macrophages by activating lysosomal P450 and nuclear hnRNPA2B1. Sig Transduct Target Ther. 2023;8(1):22. doi:10.1038/s41392-022-01212-7
   PubMed Web of Science ®Google Scholar
• Ma J, Wei K, Zhang H, et al. Mechanisms by which dendritic cells present tumor microparticle antigens to cd8+ t cells. Cancer Immunol Res. 2018;6(9):1057–1068. doi:10.1158/2326-6066.CIR-17-0716
   PubMed Web of Science ®Google Scholar
• Sun Y, Zheng Z, Zhang H, et al. Chemotherapeutic tumor microparticles combining low-dose irradiation reprogram tumor-promoting macrophages through a tumor-repopulating cell-curtailing pathway. OncoImmunology. 2017;6(6):e1309487. doi:10.1080/2162402X.2017.1309487
   PubMed Web of Science ®Google Scholar
• Palmer DH, Midgley RS, Mirza N, et al. A Phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology. 2009;49(1):124–132. doi:10.1002/hep.22626
   PubMed Web of Science ®Google Scholar
• Meko’o JLD, Xing Y, Zhang H, Lu Y, Wu J, Cao R. immunopreventive effects against murine h22 hepatocellular carcinoma in vivo by a DNA vaccine targeting a gastrin-releasing peptide. Asian Pac J Cancer Prev. 2014;15(20):9039–9043. doi:10.7314/APJCP.2014.15.20.9039
   PubMedGoogle Scholar
• Hochnadel I, Hoenicke L, Petriv N, et al. Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers. Oncogene. 2022;41(14):2039–2053. doi:10.1038/s41388-022-02222-z
   PubMed Web of Science ®Google Scholar
• Kwon S, Kim D, Park BK, et al. Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model. Oncol Rep. 2013;29(2):735–740. doi:10.3892/or.2012.2130
   PubMed Web of Science ®Google Scholar
• Cai Z, Su X, Qiu L, et al. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion. Mol Cancer. 2021;20(1):164. doi:10.1186/s12943-021-01467-8
   PubMed Web of Science ®Google Scholar